Tumor progression is associated with the release of signaling substances from the primary tumor into the bloodstream. Tumor-derived cytokines are known to promote the mobilization and the recruitment of cells from the bone marrow, including endothelial progenitor cells (EPC). Here, we examined whether such paracrine influence could also influence the capacity of EPC to interfere with circulating metastatic cells. We therefore consecutively injected EPC prestimulated by tumor-conditioned medium (EPC-CM) and luciferase-expressing B16 melanoma cells to mice. A net decrease in metastases spreading (vs. nonstimulated EPC) led us to carry out a 2-dimensional difference gel electrophoresis (2D-DIGE) proteomic study to identify possible mediators of EPC-driven protection. Among 33 proteins exhibiting significant changes in expression, secreted protein, acidic and rich in cysteine (SPARC) presented the highest induction after EPC exposure to CM. We then showed that contrary to control EPC, SPARC-silenced EPC were not able to reduce the extent of metastases when injected with B16 melanoma cells. Using adhesion tests and the hanging drop assay, we further documented that cell-cell interactions between EPC-CM and melanoma cells were promoted in a SPARC-dependent manner. This interaction led to the engulfment of melanoma cells by EPC-CM, a process prevented by SPARC silencing and mimicked by recombinant SPARC. Finally, we showed that contrary to melanoma cells, the prometastatic human breast cancer cell line MDA-MB231-D3H2 reduced SPARC expression in human EPC and stimulated metastases spreading. Our findings unravel the influence of tumor cells on EPC phenotypes through a SPARC-driven accentuation of macrophagic capacity associated with limitations to metastatic spread. Cancer Res; 71(14); 4748-57. Ó2011 AACR.
Introduction
Several populations of bone marrow-derived cells (BMDC) have been reported to contribute to tumor growth and metastatic progression, such as myeloid progenitors, macrophages, and endothelial progenitor cells (EPC; refs. [1] [2] [3] . The frontier between these different BMDC is not clearly established. A controversy even exists about the identity and functions of EPC, with some investigators claiming a major involvement of these cells in tumor neovascularization whereas others only reporting anecdotic recruitment in the tumor microenvironment (1, (4) (5) (6) (7) (8) . Bone marrow-derived progenitor cells are also reported to favor the formation of premetastatic niches, which precondition the environment to facilitate the implantation of tumor cells and the consecutive recruitment of other progenitor cells to promote the neovascularization of metastases (6) (7) . More recently, EPCs were documented to act as antigen-presenting cells similar to monocytes (9, 10) , confirming previous reports identifying populations of EPCs with an intermediate phenotype expressing both endothelial and monocytic/macrophagic properties (11, 12) .
Many studies exploring the role of EPCs in the tumor angiogenic process are based on the systemic injection of EPCs in tumor-or metastasis-bearing mice. One aspect underestimated in this model is the influence of cytokines released by the primary tumor in the blood stream and influencing bone marrow progenitor cells. We and others, however, showed that tumor-derived SDF-1 and VEGF interact with their cognate receptors at the surface of bone marrow EPCs (13) (14) (15) (16) . These studies allowed us to better understand the migration from the endosteal niche to the bone marrow vessel vicinity and the further EPCs intravasation step. One may therefore postulate that the phenotype of EPC still located in the bone marrow or on their way to the blood stream is more globally preconditioned by the exposure to circulating substances produced by tumor cells and other cells in the tumor microenvironment. In this study, we aimed to examine the effect of preconditioned EPCs by the tumor cell secretome on tumor progression and in particular on metastasis formation. We were actually rapidly intrigued by the capacity of such preconditioned EPCs to physically interact with tumor cells, and we set up experiments to address the possible protective effects of EPCs in reducing the survival of circulating tumor cells. We used embryonic mouse EPCs offering the advantage of easy maintenance in culture and transfectability (17) together with B16 melanoma cells to dissect the antimetastatic capacity of prechallenged EPC. Two-dimensional difference gel electrophoresis (2D-DIGE) proteomic analysis led us to identify osteonectin/secreted protein, acidic and rich in cysteine (SPARC) as the glue leading to physical interaction of preconditioned EPCs with melanoma cells and the consecutive engulfment of the latter.
Materials and Methods
Cell culture and mouse models B16 melanoma cells and MDA-MB231 breast cancer cells were obtained from the American Type Culture Collection lines where they are regularly authenticated. Cells were acquired in 2006 and 2010, respectively, stored according to the supplier's instructions, and used within 6 months after resuscitation of frozen aliquots. Human umbilical cord blood-derived EPCs (hEPC), as authenticated by Lonza, were used within 6 months of purchase. Previously established embryonic mouse EPCs (18, 19) were also used (for no more than 6 months after being thawed). In preconditioning experiments, EPCs and hEPCs were exposed for 24 hours to B16 and MDA-MB231 culture supernatants collected after a 2-day period, respectively. For animal studies, 8-week-old C57Bl/6 male or nude NMRI nu/nu female mice (Elevage Janvier) were used in experiments with mouse B16 F10 melanoma cells and human MDA-MB231 D3H2 breast cancer cells expressing luciferase (Xenogen, Caliper), respectively. In the metastasis experiments, EPCs and hEPCs (10 5 cells) were administered 24 hours before B16-luc and MDA-luc cells (10 6 cells), respectively, through i.v. or intracardiac injections. Metastases were tracked by i.p. injection of a single dose of luciferin (150 mg/kg) to anesthetized mice. Bioluminescence was detected 15 minutes after luciferin injection with an IVIS50 imaging system (Xenogen, Caliper). These procedures were approved by the local authorities according to national animal care regulations.
2D-DIGE analyses
EPCs were lysed with DIGE Labeling buffer and 25 mg of each extract (n ¼ 3 per condition) was minimally labeled with 200 pmol of amine-reactive cyanine dyes, Cy3 or Cy5 (GE Healthcare). Each gel was loaded with 25 mg of mixed labeled samples and 25 mg of a Cy2-labeled internal standard. The first dimension was performed with Immobiline DryStrips (GE Healthcare) and the second-dimension electrophoresis was carried out overnight. Gels were scanned with Ettan DIGE Imager at a resolution of 100 mm and analyzed using DeCyder Differential Analysis Software v7.0 (GE Healthcare). For sample recovery, preparative 2D gels were similarly performed with 300 mg of unlabeled proteins, and after spot picking and digestion, peptides were identified on the basis of their "peptide mass fingerprint."
Real-time PCR and shRNA silencing
Total RNA was extracted with the TriPure reagent (Roche, Belgium). Reverse transcription was performed using SuperScript II RNase H À reverse transcriptase (Invitrogen) and random hexamer primers. Sybr Green Supermix (BioRad) was used for quantitative real-time PCR (qRT-PCR). For silencing experiments, EPCs were transfected with a pLKO.1 vector coding for a short hairpin RNA (shRNA) targeting mouse SPARC sequence (Mission shRNA plasmid DNA, Sigma). Primers and shRNA sequences are provided in Supplementary Materials.
Immunoblotting, flow cytometry, and immunocytochemistry Immunoblotting was performed with antibodies against SPARC (R&D) and Tie-2 (R&D); gel loading was normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cell Signaling Technology), or actin (Sigma) antibody. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay (in situ cell death detection kit, Roche) was performed according to the manufacturer's instructions. Immunocytochemistry analysis was performed on paraformaldehyde-fixed cells. For flow cytometry characterization, cell suspensions were labeled with conjugated antibodies (described in Supplementary Materials) using a FACScan apparatus (BD Biosciences).
Cell-cell interaction, adhesion, and hanging drop assays
EPCs and B16-luc melanoma cells or hEPCs and MDA-luc breast cancer cells were prelabeled and placed in MEMa medium and submitted to gentle agitation for 24 hours in nonadherent plastic dishes. Cell-cell interaction was evaluated based on the detection of double colored aggregates. Adhesion assays were carried out in 96-well plates coated with fibronectin (Sigma, 20 mg/mL). Calcein-labeled EPCs (40,000 cells per well) were allowed to adhere for 1 hour at 37 C and detected after several washings in a Victor X4 plate reader (Perkin Elmer). For the hanging drop assay, 1.5 Â 10 4 tumor cells and 1.5 Â 10 3 progenitor cells were mixed in 30 mL full medium and then allowed to aggregate onto the inner surface of the lid of a 24-well plate for 24 hours at 37 C. To assay for tightness of cell-cell interactions, cells were subjected to shear force by passing them 10 times through standard tips. Extents of aggregated and isolated cells were determined within 20 minutes using a Zeiss Axiovert microscope.
Phagocytosis assays
Fluorescent latex beads (Sigma, L3030, 2 mm) were seeded on confluent EPCs preexposed or not to B16-luc melanoma cell conditioned medium (with a ratio of 3 beads per cell) in 12-well plates for 3 hours at 37 C; similar experiments were carried out with hEPCs preexposed to MDA-luc cell-conditioned medium. Cells were then washed 4 times to remove nonphagocytosed beads and fixed in 4% paraformaldehyde. After DAPI counterstaining, the number of beads ingested was determined using a Zeiss Axiovert microscope. In another set of experiments, B16F10 cells were labeled with calcein-AM and cultured overnight to minimize spontaneous leakage of dye. B16 cells were then added to EPCs or SPARC-KO EPCs. Cells were harvested 6 hours later and analyzed by flow cytometry after EPC counterstaining with phycoerythrin-conjugated c-kit antibody. The extents of double calcein-and c-kit positive cells were quantified using FlowJo software. In another set of experiments, calcein-labeled B16 melanoma cells were seeded in V-bottom 96-well plates in contact with EPCs (with ratios ranging from 1:50 to 1:0.5) and allowed to interact for 24 hours at 37 C. Plates were then centrifuged and 100 mL of cell supernatant was transferred into flat-bottom 96-well plates to detect possible release of calcein in a Victor X4 microplate reader (Perkin Elmer).
Statistics
Results are expressed as mean AE SEM. Student t-test and 1-way ANOVA (Tukey's post hoc test) were used where indicated. In Figs. 1-6, one asterisk designates P < 0.05 as statistically significant, and two asterisks designate P < 0.01 as statistically significant in the different experiments.
Results

Preconditioned EPCs inhibit metastasis formation
To mimic the modulation of EPC phenotype by cytokines released in the blood circulation from primary tumors and to study the potential impact on metastases formation, we set up experiments where we preexposed EPCs for 24 hours to the culture supernatant of B16 melanoma cells. We then injected i.v. prestimulated or control EPC followed by luciferase-expressing B16 melanoma cells (1:10 ratio, respectively) to track metastases formation through the detection of bioluminescence. We found that conditioned medium-exposed EPC (EPC-CM) dramatically reduced the extent of metastases as measured at day 10 postinjection. Control EPC did not influence the metastasis formation when compared with B16 melanoma cells injected alone ( Fig. 1A and B, upper panels). Using mouse 3T3 fibroblasts instead of EPCs, we failed to detect an effect of conditioned medium pretreatment on the extent of metastases spreading from B16 melanoma cells ( Fig.  1A and B, lower panels).
SPARC silencing in EPC-CM stimulates metastatic progression
We then used 2D-DIGE technology to compare the proteome of EPCs exposed or not to the tumor-conditioned medium ( Fig. 2A) . Using mass spectrometry to identify spots of interest, we identified 33 different proteins with significant (>2-fold) changes in expression ( Table 1 ). The abundance of 9 of them was increased in response to the exposure to B16 melanoma cell conditioned medium. With a $9-fold increase in expression, SPARC protein showed the largest induction. To validate the 2D-DIGE data, we then performed immunoblotting and immunocytochemistry experiments. We found a 3-fold increase in SPARC signal from lysates of EPC-CM (Fig. 2B ) and a similar increase in membrane SPARC expression on intact EPC-CM (Fig. 2C ).
To study a potential role of SPARC in the reduced metastatic progression, we used a dedicated shRNA construct. Stable transfection and further antibiotic selection led us to isolate several EPC clones. We selected one of them (named here below as SPARC-KO-EPC) showing 97% inhibition of SPARC transcript expression in control EPC by qRT-PCR ( ( Fig. 3B) . Importantly, the stimulatory effect of the tumorconditioned medium on SPARC expression was also significantly blunted in the SPARC-KO EPC clone (Fig. 3C) .
We then compared the influence of SPARC-KO EPC-CM and control EPC-CM injection on the metastatic potential of melanoma cells injected 24 hours later, as previously described (Fig. 1) . Interestingly, SPARC silencing in EPCs restored the extent of metastases formation observed when B16 melanoma cells were injected alone ( Fig. 3D and E) . To further evaluate the impact of EPCs prechallenged with tumor conditioned medium on the metastasis formation, we also used a model wherein cells were injected directly in the heart to bypass the potential cell trapping in the lungs after i.v. injection (Fig. 3F) . We found again that the preinjection of SPARC-KO EPC-CMs favored an increase in the extent of metastasis formation, as measured by detecting luciferasedriven bioluminescence 10 days later (Fig. 3G) .
SPARC silencing prevents physical interactions between EPC-CMs and melanoma cells
Because SPARC is a protein involved in cell adhesion, we then examined whether a SPARC-driven interaction between EPCs and melanoma cells could be involved in the observed reduction in metastasis formation. We first cocultured in vitro EPC-CM and B16 cells for 24 hours in a dish precluding cell attachment on plastic. Although control EPC-CM and melanoma cells formed aggregates, physical interaction between SPARC-KO EPC-CMs and tumor cells was reduced (Fig. 4A) . To further examine the capacity of EPC-CM to interact with B16 melanoma cells in a SPARC-dependent manner, we used the hanging drop assay (20) (21) (22) . A similar deficit in aggregate formation was observed when SPARC-KO EPC-CMs were used in the assay (vs. control EPC-CM; Fig. 4B ). To extract quantitative data from this assay, we counted the remaining isolated cells in the drop, leading to a mirror profile of aggregation (Fig. 4C) . The use of SPARC-KO EPC-CMs actually showed a number of isolated cells (i.e., a deficit in aggregation) similar to that observed when tumor cells were used alone in the hanging drop assay (Fig. 4C) . Interestingly, the addition of mouse recombinant SPARC to EPC mimicked the effect of conditioned medium exposure with a significant reduction in isolated cell numbers (i.e., an increased aggregation); this pro-aggregant effect of recombinant SPARC was also observed when coincubating B16 melanoma cells and SPARC-KO EPCs (Fig. 4C) .
We then examined whether fibronectin abundantly secreted at the extracellular pole of melanoma cells (23) and known to bind SPARC protein (24) could represent an intermediary ligand for EPCs. EPCs were therefore labeled with calcein and allowed to adhere on fibronectin-coated wells for 1 hour. After several washes to remove nonadherent cells, calcein signal was measured and quantified. The extent of EPC-CM adhesion on fibronectin amounted to 10-fold the level reached with control EPC (Fig. 4D) . Importantly, SPARC silencing led to a dramatic decrease in the capacity of EPCCMs to adhere on fibronectin (Fig. 4D) .
SPARC expression supports the phagocytic potential of EPC-CMs
The capacity of EPC-CMs to interact with melanoma cells led us to consider a possible macrophagic behavior of progenitor cells, which would reduce the number of tumor cells available to form metastases. We first performed flow cytometry and immunoblotting to characterize the phenotype of EPCs and EPC-CMs. EPCs used in our study were originally isolated from mouse embryos (18) and extensively characterized for their vascular progenitor potential (19, 25) . Both EPCs and EPC-CMs showed a strong expression of VEcadherin and c-kit but a lack of CD31 labeling confirming that these cells were not yet fully engaged in the endothelial lineage (Fig. 5D ). We also found that EPC-CMs were negative for myeloid markers including CD11b and Gr1 and the panhematopoietic surface antigen CD45. However, we found a significant increase in F4/80 staining of EPC-CMs (vs. EPCs) using 2 different anti-F4/80 antibodies (Fig. 5B) ; a low basal expression of macrophagic markers CD68 and F4/80 (with 1 of 2 antibodies) was also observed in unstimulated EPCs (Fig. 5B) . Of note, the isolation of circulating c-kitpositive cells from B16 melanoma-bearing mice allowed us to document a 6.2-fold increase in SPARC mRNA expression in this cell population (n ¼ 4, P < 0.01 vs. circulating c-kitpositive cells from healthy mice), thereby confirming the in vivo relevance of our in vitro model of preconditioned EPC.
The potential macrophagic feature of EPCs was confirmed in a phagocytosis assay using fluorescent microbeads. We found that, when preexposed to the tumor cell conditioned medium, EPC-CMs phagocytosed microbeads to a much larger extent than control EPCs (Fig. 5C and D) . Interestingly, SPARC silencing largely prevented this capacity to capture microbeads, and conversely, addition of recombinant mouse SPARC to nonstimulated EPC recapitulated the conditioned medium effects (Fig. 5C and D) . To more directly evaluate the ability of EPCs to phagocytose tumor cells, we seeded B16 melanoma cells labeled with calcein on confluent EPCs and SPARC-KO EPCs, stimulated or not with tumor cell conditioned media. Flow cytometry analysis performed after extensive rinsing to eliminate cells not captured by EPCs showed that EPC-CM could phagocytose tumor cells in a SPARC-dependent manner, as documented by the double staining of cells positive for calcein and c-kit (Fig. 5E) . To investigate a possible lytic effect of EPCs on melanoma cells, we examined whether tumor cells released calcein following exposure to EPCs. We did not observe any difference in the extent of calcein recovered from the coculture between B16 melanoma cells and EPC-CMs versus SPARC-KO EPC-CMs, confirming that the observed reduction in viable melanoma cells arose from engulfment and not cytolysis (Fig. 5F) ; incubation with Triton 1% was used as a control condition associated with major calcein leak from lysed B16 melanoma cells (Fig. 5F ). Finally, we also examined the extent of apoptotic cell death occurring in the lungs of mice i.v. injected with B16 melanoma cells 24 hours after EPC administration (ratio B16-EPC 10:1). Interestingly, we only found TUNEL-positive staining in the lungs of mice preadministered with EPC-CMs but failed to detect cell death signal when EPCs or SPARC-KO EPC-CMs were used, thereby supporting a role of SPARC-expressing EPCs in the reduction in metastasis formation (Fig. 5G) .
Conditioned medium from highly invasive MDA-MB231-D3H2 cells reduces SPARC functional expression in hEPC and increases metastasis spreading
We then wondered whether a lack of SPARC induction in EPC could participate in the exacerbation of the metastatic potential of more aggressive tumor cells. We used a luciferase-expressing MDA-MB231 breast cancer cell line obtained after several rounds of in vivo selection for their high metastatic potential (26) and hEPCs. We showed that hEPCs exposed to the conditioned medium of MDA-MB231-cells led to a reduction in SPARC mRNA and protein expression ( Fig. 6A and B) ; the interaction between the 2 cells types (i.e., as measured in the hanging drop assay by counting the number of isolated cells) and the macrophagic potential of hEPC-CMs (as measured with microfluorescent beads) were also significantly reduced ( Fig. 6C and D) . Finally, we showed that injection of hEPC-CM together with MDA-luc cells significantly increased metastasis spreading (Fig. 6E) . A similar increase in metastases was observed by combining mouse EPC-CMs and human MDA-luc cells (vs. mouse naïve EPC and MDA-luc; not shown).
Discussion
The major findings of this study are that (i) EPC may exert a protective role against metastasis development and that (ii) SPARC plays a key role in the capacity of EPCs to physically interact with and phagocytose tumor cells. Interestingly, expression of SPARC and associated antimetastatic effects are driven by EPC preconditioning by the tumor secretome. By exposing naïve EPCs to the culture supernatant of melanoma cells, we indeed aimed to mimic the paracrine influence of primary tumor on bone marrow progenitor cells. That EPC mobilization is under the influence of substances released by Figure 3 . SPARC shRNA reduces induction of SPARC in EPCs exposed to tumor cell conditioned medium and stimulates metastasis formation. A, bar graph represents SPARC mRNA expression in EPCs and a selected EPC clone stably transfected with a SPARC shRNA; **, P < 0.01, n ¼ 3. B, SPARC immunoblotting performed on EPCs and SPARC-KO EPCs; GAPDH immunoblotting was used as a loading control. Bar graph represents the normalized expression of SPARC in EPCs and SPARC-KO EPCs; **, P < 0.01, n ¼ 3. C, same as in B, but carried out on EPCs exposed to tumor conditioned medium. Representative pictures of bioluminescence detection in mice after i.v. (D) or intracardiac (F) injection of 10 6 luciferase-expressing B16 melanoma cells 24 hours after EPC-CM or SPARC-KO EPC-CM administration through the same route (10:1 ratio). Bar graphs represent the corresponding numbers of photons detected 7 and 10 days after i.v. injection (E) or 10 days after intracardiac injection (G); the extent of bioluminescence obtained in the absence of EPC coinjection is shown as control in E. *P < 0.05; **, P < 0.01 versus EPC-CM condition, n ¼ 12-15 mice for each group.
tumor cells is a concept well established (13) (14) (15) (16) . Here, we showed that this mobilization may also be envisioned as a defense mechanism where the macrophagic characteristics of EPCs can confer these cells with the capacity to eliminate circulating tumor cells. Conversely, the high prometastatic potential of tumor cells (e.g., MDA-MB231-D3H2 breast cancer cells) could in part arise from their capacity to switch off the SPARC-mediated macrophagic activity of host-derived circulating EPCs.
There are several reports documenting the phenotypic proximity between monocytes and EPCs suggesting either a common ancestor or at least important parenthood between these cell types (27) (28) (29) . In this study, we found that EPCs, when prechallenged with the conditioned medium of melanoma cells acquire some macrophagic features as indicated by F4/80 immunostaining (Fig. 5B ) and increased phagocytotic capacity (Fig. 5C-E) . Our data do not exclude a proangiogenic role of EPCs when primary tumors are implanted (as previously documented with the same EPC population used in this study (19) but emphasize that EPCs are not yet completely engaged in the endothelial lineage and may behave as macrophages according to the environment.
2D-DIGE experiments led us to identify SPARC as a protein, the expression of which was dramatically increased in EPCs following exposure to conditioned tumor cell media. SPARC is a calcium-binding matricellular glycoprotein that acts as an extracellular scaffolding protein (30, 31) . We observed that overexpression of SPARC induced a strong aggregation between melanoma cells and EPCs, an effect mimicked by the use of recombinant SPARC. Of note, "active" SPARC is likely to be extracellular but entrapped within the extracellular matrix, as indicated by the undetectability of native or recombinant SPARC in the EPC culture medium. The high affinity of SPARC for fibronectin supports the role of "glue" for SPARC, which could account for the favored interaction between EPCCMs and fibronectin-producing melanoma cells. This proadhesive role of SPARC differs, however, from other reports attributing antiadhesive properties to SPARC (32). Schultz and colleagues (33) documented that, according to the amounts of SPARC, both pro-and antiadhesive properties could be observed. Interestingly, using SPARC-null mice, Brekken and colleagues reported that lack of SPARC expression by the host (vs. tumor cells) enhanced tumor growth (34) . These authors actually reported that the tumor burden was increased in SPARC-KO mice after tumor cells were injected s.c. but also i.v. Similarly, we found that highly metastatic MDA-MB231-D3H2 breast cancer cells reduced SPARC expression in hEPCs in a paracrine manner, leading to a decrease in the SPARC-mediated macrophagic potential of progenitor cells and an associated increased metastatic burden. Brekken and colleagues further documented in a model of pancreatic carcinoma that increased tumor burden in the absence of host SPARC was a consequence of reduced collagen deposition but was also attributable to an immunetolerant microenvironment (35) . They actually found that macrophage recruitment and polarization to the M2 phenotype were augmented in the absence of SPARC. Together with our data identifying a role for SPARC in the phagocytic capacity of EPCs, this indicates that the expression of SPARC by hostderived macrophage-like progenitor cells directly influences the metastatic progression of the disease. More generally, these data emphasize the critical role of SPARC expressed by nontumor cells, in cancer progression, which appears at odds with the well-characterized tumorigenic role of SPARC expressed by tumor cells, in particular in melanoma (36, 37) .
In conclusion, our study unravels the influence of tumor cells on the phenotype of EPCs characterized by a SPARCdriven modulation of their macrophagic capacity. This 
+ r e c S P A R C Figure 5 . SPARC-driven macrophagic phenotype and activity of EPC-CMs. A, representative flow cytometry analyses of EPC and EPC-CM for expression of (A) c-kit, VE-cadherin, CD11b, Gr1, CD45, CD31, and CD68, and (B) F4/80 using 2 distinct F4/80 antibodies; Tie-2 immunoblotting is also shown in A. C, representative pictures of the phagocytosis of fluorescent microbeads by EPCs and SPARC-KO EPCs (exposed or not to conditioned media); the effect of recombinant mouse SPARC is also represented. D, quantification of endocytosed microbeads in corresponding conditions; **, P < 0.01, n ¼ 3. E, bar graph represents the extent of endocytosed calcein-preloaded B16 melanoma cells in different EPC populations, as determined by double staining for calcein and c-kit; *, P < 0.05; **, P < 0.01; n ¼ 3. F, bar graph represents the calcein cell content (i.e., the lack of cytolysis) after a 24 hour-coincubation between tumor cells and EPC (ratio 10:1); Triton was used as a positive control of a calcein leaking condition (n ¼ 3). G, representative pictures of TUNEL-positive staining (red) and DAPI nuclei counterstaining (blue) in lung sections from mice i.v. injected with B16 melanoma cells 24 hours after EPC, EPC-CM, and SPARC-KO EPC-CM i.v. administration (ratio B16-EPC 10:1). These pictures are representative of tumors (n ¼ 5 per group) collected 8 hours after B16 cell administration, TUNEL-positive staining was never observed in the EPC and SPARC-KO EPC-CM conditions.
observation adds new layers of complexity to the roles of EPC and SPARC. We now show that (i) besides their commonly reported capacity to stimulate angiogenesis, EPC populations can also prevent metastasis spreading, and (ii) despite a proinvasive role of SPARC when expressed in tumor cells, SPARC expression in EPCs may drive the interaction with and elimination of circulating tumor cells.
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